TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10192200
Drug: Interferon-alpha2a plus
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a plus ribavirin (1000-1200 mg/day in combination with the same dose of interferon-alpha2a for 6 months)
Study: 10192200
Drug: Interferon-alpha2a plus
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a plus ribavirin (1000-1200 mg/day)
Study: 2129094
Drug: Prophylactic anticonvulsant
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsant therapy
Study: 25282520
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg every 4 weeks for 12 weeks
Study: 25350595
Drug: Local melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local melatonin (3 mg)
Study: 23226013
Drug: Azithromycin taken
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin taken daily for one year
Study: 8150847
Drug: Topical therapeutic
Normalized name: Moisturel Therapeutic Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapeutic ultrasound followed by 10 minutes of passive stretching
Study: 8150847
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatments and stretching
Study: 3170408
Drug: met‐hGH (2.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: met‐hGH (2.67 mg/0.5 ml diluent, 3 days/wk)
Study: 3170408
Drug: Placebo (bacteriostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (bacteriostatic water, 0.5 ml, 3 days/wk)
Study: 28006886
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg dexmedetomidine
Study: 28006886
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg dexmedetomidine
Study: 24235903
Drug: Caffeine 400
Normalized name: caffeine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 400 mg taken 0 hours before bedtime
Study: 24235903
Drug: Caffeine 400
Normalized name: caffeine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 400 mg taken 3 hours before bedtime
Study: 24235903
Drug: Caffeine 400
Normalized name: caffeine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 400 mg taken 6 hours before bedtime
Study: 21336736
Drug: Gastrodin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrodin (40 mg/kg)
Study: 12578152
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg after an overnight fast
Study: 12578152
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg after a standard high-fat breakfast
Study: 12578152
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg (both fasting and non-fasting)
Study: 10099075
Drug: bisoprolol/6.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol/6.25 mg HCTZ (n = 155)
Study: 7857500
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract LI 160 (300 mg three times daily for 4 weeks)
Study: 1067690
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with penicillins or cephalosporins
Study: 31657590
Drug: ENHANCE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENHANCE intervention (original treatment condition)
Study: 28116876
Drug: EPI® technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI® technique in combination with a standardized APT program
Study: 26162594
Drug: I-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I-gel size 2 (group I)
Study: 21641077
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser therapy (FLT) at 10 mJ/microbeam, coverage 35% to 45%, and topical bleaching
Study: 21641077
Drug: Topical bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bleaching alone
Study: 21641077
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser therapy (FLT)
Study: 18516011
Drug: 10 day-sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 day-sequential therapy (20 mg of omeprazole, 1.0 g of amoxicillin for the first 5 days, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole for the remaining 5 days)
Study: 18516011
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple therapy (20 mg of omeprazole, 1.0 g of amoxicillin, 500 mg of clarithromycin for 1 week)
Study: 10541299
Drug: NESP (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP (equivalent peptide mass) intravenous
Study: 10541299
Drug: NESP (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP (equivalent peptide mass) subcutaneous
Study: 2233588
Drug: Senna preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna preparation
Study: 2233588
Drug: Combined laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined laxative agent
Study: 263355
Drug: L-dopa (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (1.0 g)
Study: 28318988
Drug: Butorphanol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (2 mg kg−1 intravenously)
Study: 28318988
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg kg−1 intravenously)
Study: 17877624
Drug: Active bleaching
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active bleaching treatment for teeth whitening
Study: 7895756
Drug: serum preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: serum preparation (BISEKO)
Study: 2565392
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of metoprolol p.o.
Study: 2565392
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of oxprenolol p.o.
Study: 21831465
Drug: RT-CT (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-CT (radiotherapy and chemotherapy) - 64Gy in 5 weeks with synchronous CDDP 100mg/m² on days 2, 16, and 30 and 5FU 1000mg/m² on days 1-5 and 29-33, followed by two adjuvant cycles of CDDP-5FU for good responders.
Study: 19720908
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg by mouth twice daily for 4 to 6 weeks
Study: 17043926
Drug: 10/20 mg
Normalized name: Caduet 10/20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/20 mg Memantine per day
Study: 16481295
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2) on days 1 and 8, and Carboplatin (target AUC of 5.0 mg/ml) on day 1, in a 21‐day cycle
Study: 16481295
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Carboplatin combination chemotherapy
Study: 12934847
Drug: DTaP-IPV/Hib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV/Hib combination vaccine administered in a single injection
Study: 12934847
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of DTaP-IPV and Hib
Study: 10546697
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dose of recombinant leptin
Study: 10546697
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg dose of recombinant leptin
Study: 10546697
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg dose of recombinant leptin
Study: 10546697
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of recombinant leptin
Study: 8932973
Drug: Monthly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly phone calls for clinic monitoring and annual patient exams.
Study: 7036334
Drug: Guanfacine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (average dose 2.6 mg daily)
Study: 7036334
Drug: Alpha-methyldopa (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa (average dose 750 mg daily)
Study: 26365454
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention along with lifestyle modifications (listening to raga bhimpalas played on flute for 15min daily for at least 5 days/week for 3 months)
Study: 23578975
Drug: Ischemic preconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic preconditioning (IPC) treatment involving 3 periods of 5‐min occlusion at 220 mmHg
Study: 23578975
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment involving 3 periods of 5‐min occlusion at 50 mmHg
Study: 21896877
Drug: Guava juice
Normalized name: guava juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guava juice (300 mL containing ∼200 mg of ascorbic acid)
Study: 19947275
Drug: Combined auricular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined auricular point injection and superficial anesthesia (Group A)
Study: 9039200
Drug: Butenafine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butenafine 1% cream applied twice daily for 1 week
Study: 9039200
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied twice daily for 1 week
Study: 7705374
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g d‐1)
Study: 31246050
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) followed by Imagery Rehearsal Therapy (IRT) and Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Study: 31246050
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) followed by supportive care therapy (SCT)
Study: 26102252
Drug: Dilmapimod (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilmapimod (10mg continuous infusion over 24 hours)
Study: 26102252
Drug: Dilmapimod (4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilmapimod (4-hour IV infusion)
Study: 26102252
Drug: Dilmapimod (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilmapimod (24-hour IV infusion)
Study: 23384733
Drug: S(+)‐ketamine (0.57
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (0.57 mg kg(‐1) h(‐1) for 1 h)
Study: 23384733
Drug: morphine (0.065
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.065 mg kg(‐1) h(‐1) for 1 h)
Study: 16456831
Drug: Daclizumab (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (2, 2, and 1 mg/kg on days 1, 3, and 8 posttransplant)
Study: 15156439
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg per day intravenous streptomycin, kanamycin, or amikacin
Study: 15156439
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg 3 times per week intravenous streptomycin, kanamycin, or amikacin
Study: 7618049
Drug: Intravesical infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical infusion of saline solution containing 10 microM capsaicin
Study: 2529295
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of alprazolam
Study: 2529295
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of alprazolam
Study: 2529295
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg of imipramine
Study: 401600
Drug: Propantheline bromide
Normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propantheline bromide (Pro-Banthine, 30 mg)
Study: 401600
Drug: Placebo (solvent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (solvent solution)
Study: 20974645
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially with seasonal virosomal-adjuvanted influenza vaccine
Study: 20974645
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered simultaneously with seasonal virosomal-adjuvanted influenza vaccine
Study: 20974645
Drug: Seasonal virosomal-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal virosomal-adjuvanted influenza vaccine (administered sequentially or simultaneously)
Study: 20974645
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of both vaccines
Study: 20974645
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially
Study: 19493713
Drug: Amoxicillin 1g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. for 2 weeks
Study: 19493713
Drug: Amoxicillin 1g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. plus 500 mg vitamin C per day for 2 weeks
Study: 15139065
Drug: High-dose thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiotepa (750 mg/m2) and carboplatin (1600 mg/m2) with autologous stem cell transplantation (ASCT)
Study: 15139065
Drug: High-dose thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiotepa and carboplatin with ASCT
Study: 9374097
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and paclitaxel combination therapy, total doxorubicin dose limited to 360 mg/m2.
Study: 1398238
Drug: Aspirin EC
Normalized name: Aspirin EC
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin EC 300 mg once daily for seven days before cholecystectomy
Study: 29651635
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (3 capsules totaling 9 × 10^13 colony-forming units per day of Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacteria longum)
Study: 21921743
Drug: Pressure garment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure garment therapy alone
Study: 21921743
Drug: Silicone spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone spray and compression
Study: 19810584
Drug: Yoga-nidra with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-nidra with oral hypoglycaemic
Study: 19810584
Drug: Oral hypoglycaemic
Normalized name: Biguanide oral hypoglycaemic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycaemic alone
Study: 11513913
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous bolus injection of ACTH-(1-24)
Study: 8383517
Drug: Terbutaline (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (beta 2-adrenoceptor agonist)
Study: 8383517
Drug: Xamoterol (partial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (partial beta 1-agonist)
Study: 31929465
Drug: Tablets Routine
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets Routine Questionnaire (TRQ)
Study: 25963380
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (2000 mg) with air breathing
Study: 25963380
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (2000 mg) with 40% O2 breathing
Study: 21654701
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (control +102 g oat bran/day)
Study: 18053054
Drug: Local wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound care with 500 mg of levofloxacin by mouth daily
Study: 12915396
Drug: Abdominal subcutaneous
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal subcutaneous fat depots
Study: 2861630
Drug: Broxaterol 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol 0.250 mg
Study: 2861630
Drug: Broxaterol 0.500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol 0.500 mg
Study: 23063390
Drug: Distraction osteogenesis
Normalized name: Osteogenic protein 1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 4 weeks consolidation
Study: 23063390
Drug: Distraction osteogenesis
Normalized name: Osteogenic protein 1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 8 weeks consolidation
Study: 23063390
Drug: Distraction osteogenesis
Normalized name: Osteogenic protein 1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 12 weeks consolidation
Study: 11293556
Drug: Hydrocodone 10
Normalized name: HYDROCODONE 10/PPA 25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 10 mg/acetaminophen 1000 mg
Study: 10078088
Drug: cilazapril 1
Normalized name: cilazapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 1 mg daily
Study: 2582725
Drug: Ouabain (Na+/K+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ouabain (Na+/K+ ATPase inhibitor)
Study: 2582725
Drug: Phentolamine (alpha-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (alpha-adrenoceptor antagonist)
Study: 2582725
Drug: Bretylium tosylate
Normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bretylium tosylate (neurotransmitter blocker)
Study: 28267039
Drug: Baroreceptor-activating therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreceptor-activating therapy (BAT)
Study: 24727325
Drug: LCS6 G-allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCS6 G-allele carriers (n = 432 blood samples, n = 143 tumor samples)
Study: 19946241
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/daily for 2 months and 10 mg for the next 4 months
Study: 11561740
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 mcg every 6 hours
Study: 11561740
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 mcg every 4 hours
Study: 9628277
Drug: CoQ10 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 treatment (150 mg daily for 3 years)
Study: 9628277
Drug: CoQ10 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 treatment
Study: 8208451
Drug: Laryngotracheal topical
Normalized name: LARYNGOTRACHEAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngotracheal topical spray of lidocaine 4% (2 ml) in Group L
Study: 2530945
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 to 10 mg orally twice a day)
Study: 2530945
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 to 240 mg orally twice a day)
Study: 4578361
Drug: Streptomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin plus isoniazid twice a week
Study: 4578361
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of chemotherapy beyond 18 months
Study: 4578361
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months sanatorium treatment
Study: 26021752
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high EGFR, high HER2, low HER3 and low HER4 mRNA expression
Study: 21427654
Drug: Buflomedil 600
Normalized name: buflomedil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 600 mg/day for six months
Study: 1980826
Drug: Neuroleptic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic and antiparkinsonian medication
Study: 7033746
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablets taken daily for 100 days
Study: 7033746
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken daily for 100 days
Study: 25358723
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care programme (PC programme)
Study: 22008447
Drug: Citalopram (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (≤ 60 mg/day) for up to 14 weeks
Study: 16089275
Drug: Tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (150 mg/kg L-crystalline tyrosine)
Study: 10593374
Drug: Midluteal start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midluteal start of leuprolide acetate (LA) 1 mg/d, reduced to 0.5 mg/d after addition of gonadotropins (LUT)
Study: 10593374
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) pills until cycle day 0 followed by 20 microg of LA every 12 hours on cycle day 3 with addition of gonadotropins on cycle day 5 (MICRO)
Study: 8970626
Drug: 0.4 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg/day of IVIg for the first 5 days after transplantation
Study: 8970626
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IVIg treatment)
Study: 8970626
Drug: IVIg infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIg infusion
Study: 1593552
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of PGF2 alpha diluted to 20 mL in normal saline